English

DICERNA PHARMACEUTICALS INC

EDGAR

DRNA Quarterly report (10-Q) · filed 2021-11-09

150 filing records in this dataset, filed from 2013-12-31 to 2021-11-09. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

63 million USD

2021 Q3 · USD

Exact inputs and evidence

Revenue: 62954000 USD Source

Operating margin

-32.2%

2021 Q3 · %

Exact inputs and evidence

Operating Income: -20272000 USD Source
Revenue: 62954000 USD Source

Operating cash flow

-63.8 million USD

2021 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: 68353000 USD Source
Operating Cash Flow: 132137000 USD Source

Free cash flow

-63.8 million USD

2021 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: 68353000 USD Source
Operating Cash Flow: 132137000 USD Source
Capital Expenditure: 8240000 USD Source
Capital Expenditure: 8223000 USD Source

Cash and cash equivalents: 166 million USD 2021-09-30 Source
Exact value

165756000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 77.8 million shares 2021-09-30 Source
Exact value

77834693 shares

Reported share-count change

4.22% · 3.15 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

74680999 shares · 2020-09-30· Source
77834693 shares · 2021-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

193 million USD

2020-10-01 – 2021-09-30

Exact inputs and evidence

Revenue: 164307000 USD · 2020-01-01 – 2020-12-31 Source
Revenue: 123351000 USD · 2020-01-01 – 2020-09-30 Source
Revenue: 47603000 USD · 2021-01-01 – 2021-03-31 Source
Revenue: 41337000 USD · 2021-04-01 – 2021-06-30 Source
Revenue: 62954000 USD · 2021-07-01 – 2021-09-30 Source

Net income

-124 million USD

2020-10-01 – 2021-09-30

Exact inputs and evidence

Net income: -112747000 USD · 2020-01-01 – 2020-12-31 Source
Net income: -76161000 USD · 2020-01-01 – 2020-09-30 Source
Net income: -29965000 USD · 2021-01-01 – 2021-03-31 Source
Net income: -40815000 USD · 2021-04-01 – 2021-06-30 Source
Net income: -17072000 USD · 2021-07-01 – 2021-09-30 Source

Operating cash flow

21.1 million USD

2020-10-01 – 2021-09-30

Exact inputs and evidence

Operating cash flow: 175112000 USD · 2020-01-01 – 2020-12-31 Source
Operating cash flow: 222415000 USD · 2020-01-01 – 2020-09-30 Source
Operating cash flow: -26700000 USD · 2021-01-01 – 2021-03-31 Source
Operating cash flow: 132137000 USD · 2021-01-01 – 2021-06-30 Source
Operating cash flow: -26700000 USD · 2021-01-01 – 2021-03-31 Source
Operating cash flow: 68353000 USD · 2021-01-01 – 2021-09-30 Source
Operating cash flow: 132137000 USD · 2021-01-01 – 2021-06-30 Source

Capital expenditure

12.5 million USD

2020-10-01 – 2021-09-30

Exact inputs and evidence

Capital expenditure: 11747000 USD · 2020-01-01 – 2020-12-31 Source
Capital expenditure: 7494000 USD · 2020-01-01 – 2020-09-30 Source
Capital expenditure: 3378000 USD · 2021-01-01 – 2021-03-31 Source
Capital expenditure: 8223000 USD · 2021-01-01 – 2021-06-30 Source
Capital expenditure: 3378000 USD · 2021-01-01 – 2021-03-31 Source
Capital expenditure: 8240000 USD · 2021-01-01 – 2021-09-30 Source
Capital expenditure: 8223000 USD · 2021-01-01 – 2021-06-30 Source

Free cash flow

8.56 million USD

2020-10-01 – 2021-09-30

Exact inputs and evidence

Operating cash flow: 175112000 USD · 2020-01-01 – 2020-12-31 Source
Operating cash flow: 222415000 USD · 2020-01-01 – 2020-09-30 Source
Operating cash flow: -26700000 USD · 2021-01-01 – 2021-03-31 Source
Operating cash flow: 132137000 USD · 2021-01-01 – 2021-06-30 Source
Operating cash flow: -26700000 USD · 2021-01-01 – 2021-03-31 Source
Operating cash flow: 68353000 USD · 2021-01-01 – 2021-09-30 Source
Operating cash flow: 132137000 USD · 2021-01-01 – 2021-06-30 Source
Capital expenditure: 11747000 USD · 2020-01-01 – 2020-12-31 Source
Capital expenditure: 7494000 USD · 2020-01-01 – 2020-09-30 Source
Capital expenditure: 3378000 USD · 2021-01-01 – 2021-03-31 Source
Capital expenditure: 8223000 USD · 2021-01-01 – 2021-06-30 Source
Capital expenditure: 3378000 USD · 2021-01-01 – 2021-03-31 Source
Capital expenditure: 8240000 USD · 2021-01-01 – 2021-09-30 Source
Capital expenditure: 8223000 USD · 2021-01-01 – 2021-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2021-11-09.

Financial data available through: 2020-12-31.

Coverage by financial measure

Revenue: 9 of 11 periods available· newest 2020-12-31
Operating income: 8 of 11 periods available· newest 2020-12-31
Net income: 9 of 11 periods available· newest 2020-12-31
Operating cash flow: 9 of 11 periods available· newest 2020-12-31
Capital expenditure: 9 of 11 periods available· newest 2020-12-31
Total assets: 8 of 11 periods available· newest 2020-12-31
Total liabilities: 8 of 11 periods available· newest 2020-12-31
Current assets: 8 of 11 periods available· newest 2020-12-31
Current liabilities: 8 of 11 periods available· newest 2020-12-31
Cash and cash equivalents: 9 of 11 periods available· newest 2020-12-31
long term debt: No compatible figures in this window
Shares outstanding: 8 of 11 periods available· newest 2020-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+587.4%

Prior period

USD 23.9 million

2019-01-01 – 2019-12-31
Current period

USD 164.31 million

2020-01-01 – 2020-12-31

Exact inputs and evidence

164307000 − 23904000 = 140403000 USD

23904000 USD · 2019-01-01 – 2019-12-31
Inspect prior input Prior source
164307000 USD · 2020-01-01 – 2020-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · DICERNA PHARMACEUTICALS INC · 2020-12-31 DICERNA PHARMACEUTICALS INC (edgar:1399529) Year-over-year change in Revenue: 140403000 USD Concept: fundies:Revenue Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T15:48:27Z Snapshot: 617957a68289bcdd08905de592adeaf6605088ace1dad10ef67585a7324ab889 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1399529?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 164307000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000139952921000042/drna-20201231.htm#2067276 Filing: 000139952921000042 Input fundies:Revenue: 23904000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000139952921000042/drna-20201231.htm#2068652 Filing: 000139952921000042
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 7.71 million

Prior period

−USD 120.46 million

2019-01-01 – 2019-12-31
Current period

−USD 112.75 million

2020-01-01 – 2020-12-31

Exact inputs and evidence

-112747000 − -120459000 = 7712000 USD

-120459000 USD · 2019-01-01 – 2019-12-31
Inspect prior input Prior source
-112747000 USD · 2020-01-01 – 2020-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · DICERNA PHARMACEUTICALS INC · 2020-12-31 DICERNA PHARMACEUTICALS INC (edgar:1399529) Year-over-year change in Net income: 7712000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T15:48:27Z Snapshot: 617957a68289bcdd08905de592adeaf6605088ace1dad10ef67585a7324ab889 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1399529?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -112747000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000139952921000042/drna-20201231.htm#1443353 Filing: 000139952921000042 Input fundies:NetIncome: -120459000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000139952921000042/drna-20201231.htm#1444317 Filing: 000139952921000042
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 175.8 million

Prior period

−USD 692,000

2019-01-01 – 2019-12-31
Current period

USD 175.11 million

2020-01-01 – 2020-12-31

Exact inputs and evidence

175112000 − -692000 = 175804000 USD

-692000 USD · 2019-01-01 – 2019-12-31
Inspect prior input Prior source
175112000 USD · 2020-01-01 – 2020-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · DICERNA PHARMACEUTICALS INC · 2020-12-31 DICERNA PHARMACEUTICALS INC (edgar:1399529) Year-over-year change in Operating cash flow: 175804000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T15:48:27Z Snapshot: 617957a68289bcdd08905de592adeaf6605088ace1dad10ef67585a7324ab889 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1399529?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: 175112000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000139952921000042/drna-20201231.htm#1496290 Filing: 000139952921000042 Input fundies:OperatingCashFlow: -692000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000139952921000042/drna-20201231.htm#1497335 Filing: 000139952921000042
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+85%

Prior period

USD 6.35 million

2019-01-01 – 2019-12-31
Current period

USD 11.75 million

2020-01-01 – 2020-12-31

Exact inputs and evidence

11747000 − 6349000 = 5398000 USD

6349000 USD · 2019-01-01 – 2019-12-31
Inspect prior input Prior source
11747000 USD · 2020-01-01 – 2020-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · DICERNA PHARMACEUTICALS INC · 2020-12-31 DICERNA PHARMACEUTICALS INC (edgar:1399529) Year-over-year change in Capital expenditure: 5398000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T15:48:27Z Snapshot: 617957a68289bcdd08905de592adeaf6605088ace1dad10ef67585a7324ab889 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1399529?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 11747000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000139952921000042/drna-20201231.htm#1506962 Filing: 000139952921000042 Input fundies:CapitalExpenditure: 6349000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000139952921000042/drna-20201231.htm#1507948 Filing: 000139952921000042
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2020 2020-01-01 – 2020-12-31

Revenue USD 164.31 million 100% of revenue
Operating costs Derived USD 277.52 million 169% of revenue
Operating income −USD 113.21 million −69% of revenue
Tax, interest and other Derived −USD 461,000 −0.3% of revenue
Net income −USD 112.75 million −69% of revenue

Cash

Operating cash flow USD 175.11 million 107% of revenue
Capital expenditure USD 11.75 million 7.1% of revenue
Free cash flow Derived USD 163.37 million 99% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2012 Not shown: operating income or net income is not reported.
2013 Not shown: operating income or net income is not reported.
2014 Not shown: operating income or net income is not reported.
2015 Operating loss: operating costs were 34,354% of revenue.
2016 Not shown: operating income or net income is not reported.
2017 Operating loss: operating costs were 5,997% of revenue.
2018 Operating loss: operating costs were 1,563% of revenue.
2019 Operating loss: operating costs were 636% of revenue.
2020 Operating loss: operating costs were 169% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2012 2012-01-01 – 2012-12-31	7015000	Unavailable	Unavailable	Unavailable	-10121000	-15857000 Derived	Source 2012-01-01 – 2012-12-31: 7015000 USD Inspect Revenue Open source 2012-01-01 – 2012-12-31: -10121000 USD Inspect Net Income Open source 2012-01-01 – 2012-12-31: -15737000 USD Inspect Operating Cash Flow Open source 2012-01-01 – 2012-12-31: 120000 USD Inspect Capital Expenditure Open source
2013 2013-01-01 – 2013-12-31	0	17378000 Derived	-17378000	1140000 Derived	-18518000	-11357000 Derived	Source 2013-01-01 – 2013-12-31: 0 USD Inspect Revenue Open source 2013-01-01 – 2013-12-31: -17378000 USD Inspect Operating Income Open source 2013-01-01 – 2013-12-31: -18518000 USD Inspect Net Income Open source 2013-01-01 – 2013-12-31: -10944000 USD Inspect Operating Cash Flow Open source 2013-01-01 – 2013-12-31: 413000 USD Inspect Capital Expenditure Open source
2014 2014-01-01 – 2014-12-31	0	45101000 Derived	-45101000	2838000 Derived	-47939000	-36777000 Derived	Source 2014-01-01 – 2014-12-31: 0 USD Inspect Revenue Open source 2014-01-01 – 2014-12-31: -45101000 USD Inspect Operating Income Open source 2014-01-01 – 2014-12-31: -47939000 USD Inspect Net Income Open source 2014-01-01 – 2014-12-31: -34764000 USD Inspect Operating Cash Flow Open source 2014-01-01 – 2014-12-31: 2013000 USD Inspect Capital Expenditure Open source
2015 2015-01-01 – 2015-12-31	184000	63211000 Derived	-63027000	-188000 Derived	-62839000	-49933000 Derived	Source 2015-01-01 – 2015-12-31: 184000 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: -63027000 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: -62839000 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: -48799000 USD Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 1134000 USD Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	0	59748000 Derived	-59748000	-235000 Derived	-59513000	-49196000 Derived	Source 2016-01-01 – 2016-12-31: 0 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -59748000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -59513000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -48747000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 449000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	1030000	61769000 Derived	-60739000	-539000 Derived	-60200000	-45460000 Derived	Source 2017-01-01 – 2017-12-31: 1030000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -60739000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -60200000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -45327000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 133000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	6176000	96528000 Derived	-90352000	-1499000 Derived	-88853000	17939000 Derived	Source 2018-01-01 – 2018-12-31: 6176000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -90352000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -88853000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: 18298000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 359000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	23904000	152090000 Derived	-128186000	-7727000 Derived	-120459000	-7041000 Derived	Source 2019-01-01 – 2019-12-31: 23904000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -128186000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -120459000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -692000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 6349000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	164307000	277515000 Derived	-113208000	-461000 Derived	-112747000	163365000 Derived	Source 2020-01-01 – 2020-12-31: 164307000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -113208000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -112747000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: 175112000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 11747000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 164.3M 2020

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20122012-12-31	Revenue	7015000	Revenue: 7015000 Open source
20132013-12-31	Revenue	0	Revenue: 0 Open source
20142014-12-31	Revenue	0	Revenue: 0 Open source
20152015-12-31	Revenue	184000	Revenue: 184000 Open source
20162016-12-31	Revenue	0	Revenue: 0 Open source
20172017-12-31	Revenue	1030000	Revenue: 1030000 Open source
20182018-12-31	Revenue	6176000	Revenue: 6176000 Open source
20192019-12-31	Revenue	23904000	Revenue: 23904000 Open source
20202020-12-31	Revenue	164307000	Revenue: 164307000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

587.4% 2020

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20122012-12-31	Year over year	No prior comparable period	Revenue: 7015000 Open source
20132013-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 7015000 Open source
20142014-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20152015-12-31	Year over year	No prior comparable period	Revenue: 184000 Open source Revenue: 0 Open source
20162016-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 184000 Open source
20172017-12-31	Year over year	No prior comparable period	Revenue: 1030000 Open source Revenue: 0 Open source
20182018-12-31	Year over year	499.6%	Revenue: 6176000 Open source Revenue: 1030000 Open source
20192019-12-31	Year over year	287%	Revenue: 23904000 Open source Revenue: 6176000 Open source
20202020-12-31	Year over year	587.4%	Revenue: 164307000 Open source Revenue: 23904000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -68.9% 2020

Net margin -68.6% 2020

Free cash flow margin 99.4% 2020

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
2012-12-31	Operating margin	Not reported	Revenue: 7015000 Open source
20132013-12-31	Operating margin	Not reported	Operating Income: -17378000 Open source Revenue: 0 Open source
20142014-12-31	Operating margin	Not reported	Operating Income: -45101000 Open source Revenue: 0 Open source
20152015-12-31	Operating margin	-34,253.8%	Operating Income: -63027000 Open source Revenue: 184000 Open source
20162016-12-31	Operating margin	Not reported	Operating Income: -59748000 Open source Revenue: 0 Open source
20172017-12-31	Operating margin	-5,897%	Operating Income: -60739000 Open source Revenue: 1030000 Open source
20182018-12-31	Operating margin	-1,463%	Operating Income: -90352000 Open source Revenue: 6176000 Open source
20192019-12-31	Operating margin	-536.3%	Operating Income: -128186000 Open source Revenue: 23904000 Open source
20202020-12-31	Operating margin	-68.9%	Operating Income: -113208000 Open source Revenue: 164307000 Open source
20122012-12-31	Net margin	-144.3%	Net Income: -10121000 Open source Revenue: 7015000 Open source
20132013-12-31	Net margin	Not reported	Net Income: -18518000 Open source Revenue: 0 Open source
20142014-12-31	Net margin	Not reported	Net Income: -47939000 Open source Revenue: 0 Open source
20152015-12-31	Net margin	-34,151.6%	Net Income: -62839000 Open source Revenue: 184000 Open source
20162016-12-31	Net margin	Not reported	Net Income: -59513000 Open source Revenue: 0 Open source
20172017-12-31	Net margin	-5,844.7%	Net Income: -60200000 Open source Revenue: 1030000 Open source
20182018-12-31	Net margin	-1,438.7%	Net Income: -88853000 Open source Revenue: 6176000 Open source
20192019-12-31	Net margin	-503.9%	Net Income: -120459000 Open source Revenue: 23904000 Open source
20202020-12-31	Net margin	-68.6%	Net Income: -112747000 Open source Revenue: 164307000 Open source
20122012-12-31	Free cash flow margin	-226%	Revenue: 7015000 Open source Operating Cash Flow: -15737000 Open source Capital Expenditure: 120000 Open source
20132013-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -10944000 Open source Capital Expenditure: 413000 Open source
20142014-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -34764000 Open source Capital Expenditure: 2013000 Open source
20152015-12-31	Free cash flow margin	-27,137.5%	Revenue: 184000 Open source Operating Cash Flow: -48799000 Open source Capital Expenditure: 1134000 Open source
20162016-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -48747000 Open source Capital Expenditure: 449000 Open source
20172017-12-31	Free cash flow margin	-4,413.6%	Revenue: 1030000 Open source Operating Cash Flow: -45327000 Open source Capital Expenditure: 133000 Open source
20182018-12-31	Free cash flow margin	290.5%	Revenue: 6176000 Open source Operating Cash Flow: 18298000 Open source Capital Expenditure: 359000 Open source
20192019-12-31	Free cash flow margin	-29.5%	Revenue: 23904000 Open source Operating Cash Flow: -692000 Open source Capital Expenditure: 6349000 Open source
20202020-12-31	Free cash flow margin	99.4%	Revenue: 164307000 Open source Operating Cash Flow: 175112000 Open source Capital Expenditure: 11747000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD 175.1M 2020

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20122012-12-31	Operating cash flow	-15737000	Operating Cash Flow: -15737000 Open source
20132013-12-31	Operating cash flow	-10944000	Operating Cash Flow: -10944000 Open source
20142014-12-31	Operating cash flow	-34764000	Operating Cash Flow: -34764000 Open source
20152015-12-31	Operating cash flow	-48799000	Operating Cash Flow: -48799000 Open source
20162016-12-31	Operating cash flow	-48747000	Operating Cash Flow: -48747000 Open source
20172017-12-31	Operating cash flow	-45327000	Operating Cash Flow: -45327000 Open source
20182018-12-31	Operating cash flow	18298000	Operating Cash Flow: 18298000 Open source
20192019-12-31	Operating cash flow	-692000	Operating Cash Flow: -692000 Open source
20202020-12-31	Operating cash flow	175112000	Operating Cash Flow: 175112000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD 163.4M 2020

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20122012-12-31	Free cash flow	-15857000	Operating Cash Flow: -15737000 Open source Capital Expenditure: 120000 Open source
20132013-12-31	Free cash flow	-11357000	Operating Cash Flow: -10944000 Open source Capital Expenditure: 413000 Open source
20142014-12-31	Free cash flow	-36777000	Operating Cash Flow: -34764000 Open source Capital Expenditure: 2013000 Open source
20152015-12-31	Free cash flow	-49933000	Operating Cash Flow: -48799000 Open source Capital Expenditure: 1134000 Open source
20162016-12-31	Free cash flow	-49196000	Operating Cash Flow: -48747000 Open source Capital Expenditure: 449000 Open source
20172017-12-31	Free cash flow	-45460000	Operating Cash Flow: -45327000 Open source Capital Expenditure: 133000 Open source
20182018-12-31	Free cash flow	17939000	Operating Cash Flow: 18298000 Open source Capital Expenditure: 359000 Open source
20192019-12-31	Free cash flow	-7041000	Operating Cash Flow: -692000 Open source Capital Expenditure: 6349000 Open source
20202020-12-31	Free cash flow	163365000	Operating Cash Flow: 175112000 Open source Capital Expenditure: 11747000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

80.5% 2020

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2012-12-31	Liabilities / assets	Not reported	No source recorded
20132013-12-31	Liabilities / assets	17%	Total Liabilities: 8467000 Open source Total Assets: 49794000 Open source
20142014-12-31	Liabilities / assets	5.1%	Total Liabilities: 5265000 Open source Total Assets: 103605000 Open source
20152015-12-31	Liabilities / assets	9%	Total Liabilities: 9001000 Open source Total Assets: 100023000 Open source
20162016-12-31	Liabilities / assets	19.6%	Total Liabilities: 10044000 Open source Total Assets: 51252000 Open source
20172017-12-31	Liabilities / assets	16.5%	Total Liabilities: 19916000 Open source Total Assets: 121002000 Open source
20182018-12-31	Liabilities / assets	50.9%	Total Liabilities: 208348000 Open source Total Assets: 409041000 Open source
20192019-12-31	Liabilities / assets	74.5%	Total Liabilities: 445214000 Open source Total Assets: 597409000 Open source
20202020-12-31	Liabilities / assets	80.5%	Total Liabilities: 570092000 Open source Total Assets: 707846000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

3.48× 2020

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2012-12-31	Current assets / current liabilities	Not reported	No source recorded
20132013-12-31	Current assets / current liabilities	6.34×	Current Assets: 48653000 Open source Current Liabilities: 7678000 Open source
20142014-12-31	Current assets / current liabilities	18.86×	Current Assets: 97316000 Open source Current Liabilities: 5159000 Open source
20152015-12-31	Current assets / current liabilities	10.68×	Current Assets: 96141000 Open source Current Liabilities: 9001000 Open source
20162016-12-31	Current assets / current liabilities	4.76×	Current Assets: 47826000 Open source Current Liabilities: 10044000 Open source
20172017-12-31	Current assets / current liabilities	7.05×	Current Assets: 118676000 Open source Current Liabilities: 16826000 Open source
20182018-12-31	Current assets / current liabilities	4.31×	Current Assets: 405514000 Open source Current Liabilities: 94055000 Open source
20192019-12-31	Current assets / current liabilities	2.3×	Current Assets: 556169000 Open source Current Liabilities: 241735000 Open source
20202020-12-31	Current assets / current liabilities	3.48×	Current Assets: 618703000 Open source Current Liabilities: 177938000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2012 2012-01-01 – 2012-12-31	−USD 10.12 million Exact value Exact value: -10121000 USD 2012-01-01 – 2012-12-31: -10121000 USD Inspect Net Income Open source Share or cite Citation for Net Income · DICERNA PHARMACEUTICALS INC · 2012-12-31 DICERNA PHARMACEUTICALS INC (edgar:1399529) Net Income: -10121000 USD Concept: fundies:NetIncome Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T15:48:27Z Snapshot: 617957a68289bcdd08905de592adeaf6605088ace1dad10ef67585a7324ab889 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1399529/explain?concept=fundies%3ANetIncome&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:NetIncome: -10121000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000119312515089221/drna-20141231.xml#785513 Filing: 000119312515089221 The citation records this snapshot. The page link may show a newer release later.	−USD 15.74 million Exact value Exact value: -15737000 USD 2012-01-01 – 2012-12-31: -15737000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · DICERNA PHARMACEUTICALS INC · 2012-12-31 DICERNA PHARMACEUTICALS INC (edgar:1399529) Operating Cash Flow: -15737000 USD Concept: fundies:OperatingCashFlow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T15:48:27Z Snapshot: 617957a68289bcdd08905de592adeaf6605088ace1dad10ef67585a7324ab889 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1399529/explain?concept=fundies%3AOperatingCashFlow&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -15737000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000119312515089221/drna-20141231.xml#780225 Filing: 000119312515089221 The citation records this snapshot. The page link may show a newer release later.	USD 120,000 Exact value Exact value: 120000 USD 2012-01-01 – 2012-12-31: 120000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · DICERNA PHARMACEUTICALS INC · 2012-12-31 DICERNA PHARMACEUTICALS INC (edgar:1399529) Capital Expenditure: 120000 USD Concept: fundies:CapitalExpenditure Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T15:48:27Z Snapshot: 617957a68289bcdd08905de592adeaf6605088ace1dad10ef67585a7324ab889 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1399529/explain?concept=fundies%3ACapitalExpenditure&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 120000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000119312515089221/drna-20141231.xml#784970 Filing: 000119312515089221 The citation records this snapshot. The page link may show a newer release later.	−USD 15.86 million Calculation and evidence -15737000 − 120000 USD Exact free cash flow: -15857000 USD 2012-01-01 – 2012-12-31: -15737000 USD · Inspect Operating Cash Flow · Source 2012-01-01 – 2012-12-31: 120000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · DICERNA PHARMACEUTICALS INC · 2012-12-31 DICERNA PHARMACEUTICALS INC (edgar:1399529) Free cash flow: -15857000 USD Concept: free-cash-flow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T15:48:27Z Snapshot: 617957a68289bcdd08905de592adeaf6605088ace1dad10ef67585a7324ab889 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1399529?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -15737000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000119312515089221/drna-20141231.xml#780225 Filing: 000119312515089221 Input fundies:CapitalExpenditure: 120000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000119312515089221/drna-20141231.xml#784970 Filing: 000119312515089221 The citation records this snapshot. The page link may show a newer release later.
2013 2013-01-01 – 2013-12-31	−USD 18.52 million Exact value Exact value: -18518000 USD 2013-01-01 – 2013-12-31: -18518000 USD Inspect Net Income Open source Share or cite Citation for Net Income · DICERNA PHARMACEUTICALS INC · 2013-12-31 DICERNA PHARMACEUTICALS INC (edgar:1399529) Net Income: -18518000 USD Concept: fundies:NetIncome Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T15:48:27Z Snapshot: 617957a68289bcdd08905de592adeaf6605088ace1dad10ef67585a7324ab889 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1399529/explain?concept=fundies%3ANetIncome&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:NetIncome: -18518000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000119312516500111/drna-20151231.xml#81677 Filing: 000119312516500111 The citation records this snapshot. The page link may show a newer release later.	−USD 10.94 million Exact value Exact value: -10944000 USD 2013-01-01 – 2013-12-31: -10944000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · DICERNA PHARMACEUTICALS INC · 2013-12-31 DICERNA PHARMACEUTICALS INC (edgar:1399529) Operating Cash Flow: -10944000 USD Concept: fundies:OperatingCashFlow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T15:48:27Z Snapshot: 617957a68289bcdd08905de592adeaf6605088ace1dad10ef67585a7324ab889 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1399529/explain?concept=fundies%3AOperatingCashFlow&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -10944000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000119312516500111/drna-20151231.xml#78604 Filing: 000119312516500111 The citation records this snapshot. The page link may show a newer release later.	USD 413,000 Exact value Exact value: 413000 USD 2013-01-01 – 2013-12-31: 413000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · DICERNA PHARMACEUTICALS INC · 2013-12-31 DICERNA PHARMACEUTICALS INC (edgar:1399529) Capital Expenditure: 413000 USD Concept: fundies:CapitalExpenditure Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T15:48:27Z Snapshot: 617957a68289bcdd08905de592adeaf6605088ace1dad10ef67585a7324ab889 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1399529/explain?concept=fundies%3ACapitalExpenditure&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 413000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000119312516500111/drna-20151231.xml#81412 Filing: 000119312516500111 The citation records this snapshot. The page link may show a newer release later.	−USD 11.36 million Calculation and evidence -10944000 − 413000 USD Exact free cash flow: -11357000 USD 2013-01-01 – 2013-12-31: -10944000 USD · Inspect Operating Cash Flow · Source 2013-01-01 – 2013-12-31: 413000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · DICERNA PHARMACEUTICALS INC · 2013-12-31 DICERNA PHARMACEUTICALS INC (edgar:1399529) Free cash flow: -11357000 USD Concept: free-cash-flow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T15:48:27Z Snapshot: 617957a68289bcdd08905de592adeaf6605088ace1dad10ef67585a7324ab889 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1399529?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -10944000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000119312516500111/drna-20151231.xml#78604 Filing: 000119312516500111 Input fundies:CapitalExpenditure: 413000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000119312516500111/drna-20151231.xml#81412 Filing: 000119312516500111 The citation records this snapshot. The page link may show a newer release later.
2014 2014-01-01 – 2014-12-31	−USD 47.94 million Exact value Exact value: -47939000 USD 2014-01-01 – 2014-12-31: -47939000 USD Inspect Net Income Open source Share or cite Citation for Net Income · DICERNA PHARMACEUTICALS INC · 2014-12-31 DICERNA PHARMACEUTICALS INC (edgar:1399529) Net Income: -47939000 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T15:48:27Z Snapshot: 617957a68289bcdd08905de592adeaf6605088ace1dad10ef67585a7324ab889 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1399529/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: -47939000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000119312517104169/drna-20161231.xml#71294 Filing: 000119312517104169 The citation records this snapshot. The page link may show a newer release later.	−USD 34.76 million Exact value Exact value: -34764000 USD 2014-01-01 – 2014-12-31: -34764000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · DICERNA PHARMACEUTICALS INC · 2014-12-31 DICERNA PHARMACEUTICALS INC (edgar:1399529) Operating Cash Flow: -34764000 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T15:48:27Z Snapshot: 617957a68289bcdd08905de592adeaf6605088ace1dad10ef67585a7324ab889 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1399529/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -34764000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000119312517104169/drna-20161231.xml#74654 Filing: 000119312517104169 The citation records this snapshot. The page link may show a newer release later.	USD 2.01 million Exact value Exact value: 2013000 USD 2014-01-01 – 2014-12-31: 2013000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · DICERNA PHARMACEUTICALS INC · 2014-12-31 DICERNA PHARMACEUTICALS INC (edgar:1399529) Capital Expenditure: 2013000 USD Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T15:48:27Z Snapshot: 617957a68289bcdd08905de592adeaf6605088ace1dad10ef67585a7324ab889 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1399529/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2013000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000119312517104169/drna-20161231.xml#75236 Filing: 000119312517104169 The citation records this snapshot. The page link may show a newer release later.	−USD 36.78 million Calculation and evidence -34764000 − 2013000 USD Exact free cash flow: -36777000 USD 2014-01-01 – 2014-12-31: -34764000 USD · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 2013000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · DICERNA PHARMACEUTICALS INC · 2014-12-31 DICERNA PHARMACEUTICALS INC (edgar:1399529) Free cash flow: -36777000 USD Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T15:48:27Z Snapshot: 617957a68289bcdd08905de592adeaf6605088ace1dad10ef67585a7324ab889 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1399529?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -34764000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000119312517104169/drna-20161231.xml#74654 Filing: 000119312517104169 Input fundies:CapitalExpenditure: 2013000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000119312517104169/drna-20161231.xml#75236 Filing: 000119312517104169 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	−USD 62.84 million Exact value Exact value: -62839000 USD 2015-01-01 – 2015-12-31: -62839000 USD Inspect Net Income Open source Share or cite Citation for Net Income · DICERNA PHARMACEUTICALS INC · 2015-12-31 DICERNA PHARMACEUTICALS INC (edgar:1399529) Net Income: -62839000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T15:48:27Z Snapshot: 617957a68289bcdd08905de592adeaf6605088ace1dad10ef67585a7324ab889 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1399529/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -62839000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000119312518075129/drna-20171231.xml#77436 Filing: 000119312518075129 The citation records this snapshot. The page link may show a newer release later.	−USD 48.8 million Exact value Exact value: -48799000 USD 2015-01-01 – 2015-12-31: -48799000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · DICERNA PHARMACEUTICALS INC · 2015-12-31 DICERNA PHARMACEUTICALS INC (edgar:1399529) Operating Cash Flow: -48799000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T15:48:27Z Snapshot: 617957a68289bcdd08905de592adeaf6605088ace1dad10ef67585a7324ab889 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1399529/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -48799000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000119312518075129/drna-20171231.xml#76327 Filing: 000119312518075129 The citation records this snapshot. The page link may show a newer release later.	USD 1.13 million Exact value Exact value: 1134000 USD 2015-01-01 – 2015-12-31: 1134000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · DICERNA PHARMACEUTICALS INC · 2015-12-31 DICERNA PHARMACEUTICALS INC (edgar:1399529) Capital Expenditure: 1134000 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T15:48:27Z Snapshot: 617957a68289bcdd08905de592adeaf6605088ace1dad10ef67585a7324ab889 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1399529/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1134000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000119312518075129/drna-20171231.xml#78423 Filing: 000119312518075129 The citation records this snapshot. The page link may show a newer release later.	−USD 49.93 million Calculation and evidence -48799000 − 1134000 USD Exact free cash flow: -49933000 USD 2015-01-01 – 2015-12-31: -48799000 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 1134000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · DICERNA PHARMACEUTICALS INC · 2015-12-31 DICERNA PHARMACEUTICALS INC (edgar:1399529) Free cash flow: -49933000 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T15:48:27Z Snapshot: 617957a68289bcdd08905de592adeaf6605088ace1dad10ef67585a7324ab889 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1399529?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -48799000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000119312518075129/drna-20171231.xml#76327 Filing: 000119312518075129 Input fundies:CapitalExpenditure: 1134000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000119312518075129/drna-20171231.xml#78423 Filing: 000119312518075129 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−USD 59.51 million Exact value Exact value: -59513000 USD 2016-01-01 – 2016-12-31: -59513000 USD Inspect Net Income Open source Share or cite Citation for Net Income · DICERNA PHARMACEUTICALS INC · 2016-12-31 DICERNA PHARMACEUTICALS INC (edgar:1399529) Net Income: -59513000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T15:48:27Z Snapshot: 617957a68289bcdd08905de592adeaf6605088ace1dad10ef67585a7324ab889 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1399529/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -59513000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000139952919000005/drna-20181231.xml#257054 Filing: 000139952919000005 The citation records this snapshot. The page link may show a newer release later.	−USD 48.75 million Exact value Exact value: -48747000 USD 2016-01-01 – 2016-12-31: -48747000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · DICERNA PHARMACEUTICALS INC · 2016-12-31 DICERNA PHARMACEUTICALS INC (edgar:1399529) Operating Cash Flow: -48747000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T15:48:27Z Snapshot: 617957a68289bcdd08905de592adeaf6605088ace1dad10ef67585a7324ab889 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1399529/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -48747000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000139952919000005/drna-20181231.xml#256419 Filing: 000139952919000005 The citation records this snapshot. The page link may show a newer release later.	USD 449,000 Exact value Exact value: 449000 USD 2016-01-01 – 2016-12-31: 449000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · DICERNA PHARMACEUTICALS INC · 2016-12-31 DICERNA PHARMACEUTICALS INC (edgar:1399529) Capital Expenditure: 449000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T15:48:27Z Snapshot: 617957a68289bcdd08905de592adeaf6605088ace1dad10ef67585a7324ab889 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1399529/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 449000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000139952919000005/drna-20181231.xml#270884 Filing: 000139952919000005 The citation records this snapshot. The page link may show a newer release later.	−USD 49.2 million Calculation and evidence -48747000 − 449000 USD Exact free cash flow: -49196000 USD 2016-01-01 – 2016-12-31: -48747000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 449000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · DICERNA PHARMACEUTICALS INC · 2016-12-31 DICERNA PHARMACEUTICALS INC (edgar:1399529) Free cash flow: -49196000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T15:48:27Z Snapshot: 617957a68289bcdd08905de592adeaf6605088ace1dad10ef67585a7324ab889 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1399529?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -48747000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000139952919000005/drna-20181231.xml#256419 Filing: 000139952919000005 Input fundies:CapitalExpenditure: 449000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000139952919000005/drna-20181231.xml#270884 Filing: 000139952919000005 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 60.2 million Exact value Exact value: -60200000 USD 2017-01-01 – 2017-12-31: -60200000 USD Inspect Net Income Open source Share or cite Citation for Net Income · DICERNA PHARMACEUTICALS INC · 2017-12-31 DICERNA PHARMACEUTICALS INC (edgar:1399529) Net Income: -60200000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T15:48:27Z Snapshot: 617957a68289bcdd08905de592adeaf6605088ace1dad10ef67585a7324ab889 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1399529/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -60200000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000139952920000009/drna-20191231.xml#300434 Filing: 000139952920000009 The citation records this snapshot. The page link may show a newer release later.	−USD 45.33 million Exact value Exact value: -45327000 USD 2017-01-01 – 2017-12-31: -45327000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · DICERNA PHARMACEUTICALS INC · 2017-12-31 DICERNA PHARMACEUTICALS INC (edgar:1399529) Operating Cash Flow: -45327000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T15:48:27Z Snapshot: 617957a68289bcdd08905de592adeaf6605088ace1dad10ef67585a7324ab889 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1399529/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -45327000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000139952920000009/drna-20191231.xml#299801 Filing: 000139952920000009 The citation records this snapshot. The page link may show a newer release later.	USD 133,000 Exact value Exact value: 133000 USD 2017-01-01 – 2017-12-31: 133000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · DICERNA PHARMACEUTICALS INC · 2017-12-31 DICERNA PHARMACEUTICALS INC (edgar:1399529) Capital Expenditure: 133000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T15:48:27Z Snapshot: 617957a68289bcdd08905de592adeaf6605088ace1dad10ef67585a7324ab889 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1399529/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 133000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000139952920000009/drna-20191231.xml#315783 Filing: 000139952920000009 The citation records this snapshot. The page link may show a newer release later.	−USD 45.46 million Calculation and evidence -45327000 − 133000 USD Exact free cash flow: -45460000 USD 2017-01-01 – 2017-12-31: -45327000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 133000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · DICERNA PHARMACEUTICALS INC · 2017-12-31 DICERNA PHARMACEUTICALS INC (edgar:1399529) Free cash flow: -45460000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T15:48:27Z Snapshot: 617957a68289bcdd08905de592adeaf6605088ace1dad10ef67585a7324ab889 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1399529?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -45327000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000139952920000009/drna-20191231.xml#299801 Filing: 000139952920000009 Input fundies:CapitalExpenditure: 133000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000139952920000009/drna-20191231.xml#315783 Filing: 000139952920000009 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 88.85 million Exact value Exact value: -88853000 USD 2018-01-01 – 2018-12-31: -88853000 USD Inspect Net Income Open source Share or cite Citation for Net Income · DICERNA PHARMACEUTICALS INC · 2018-12-31 DICERNA PHARMACEUTICALS INC (edgar:1399529) Net Income: -88853000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T15:48:27Z Snapshot: 617957a68289bcdd08905de592adeaf6605088ace1dad10ef67585a7324ab889 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1399529/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -88853000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000139952921000042/drna-20201231.htm#1445488 Filing: 000139952921000042 The citation records this snapshot. The page link may show a newer release later.	USD 18.3 million Exact value Exact value: 18298000 USD 2018-01-01 – 2018-12-31: 18298000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · DICERNA PHARMACEUTICALS INC · 2018-12-31 DICERNA PHARMACEUTICALS INC (edgar:1399529) Operating Cash Flow: 18298000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T15:48:27Z Snapshot: 617957a68289bcdd08905de592adeaf6605088ace1dad10ef67585a7324ab889 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1399529/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 18298000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000139952921000042/drna-20201231.htm#1498352 Filing: 000139952921000042 The citation records this snapshot. The page link may show a newer release later.	USD 359,000 Exact value Exact value: 359000 USD 2018-01-01 – 2018-12-31: 359000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · DICERNA PHARMACEUTICALS INC · 2018-12-31 DICERNA PHARMACEUTICALS INC (edgar:1399529) Capital Expenditure: 359000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T15:48:27Z Snapshot: 617957a68289bcdd08905de592adeaf6605088ace1dad10ef67585a7324ab889 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1399529/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 359000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000139952921000042/drna-20201231.htm#1508933 Filing: 000139952921000042 The citation records this snapshot. The page link may show a newer release later.	USD 17.94 million Calculation and evidence 18298000 − 359000 USD Exact free cash flow: 17939000 USD 2018-01-01 – 2018-12-31: 18298000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 359000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · DICERNA PHARMACEUTICALS INC · 2018-12-31 DICERNA PHARMACEUTICALS INC (edgar:1399529) Free cash flow: 17939000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T15:48:27Z Snapshot: 617957a68289bcdd08905de592adeaf6605088ace1dad10ef67585a7324ab889 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1399529?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 18298000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000139952921000042/drna-20201231.htm#1498352 Filing: 000139952921000042 Input fundies:CapitalExpenditure: 359000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000139952921000042/drna-20201231.htm#1508933 Filing: 000139952921000042 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 120.46 million Exact value Exact value: -120459000 USD 2019-01-01 – 2019-12-31: -120459000 USD Inspect Net Income Open source Share or cite Citation for Net Income · DICERNA PHARMACEUTICALS INC · 2019-12-31 DICERNA PHARMACEUTICALS INC (edgar:1399529) Net Income: -120459000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T15:48:27Z Snapshot: 617957a68289bcdd08905de592adeaf6605088ace1dad10ef67585a7324ab889 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1399529/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -120459000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000139952921000042/drna-20201231.htm#1444317 Filing: 000139952921000042 The citation records this snapshot. The page link may show a newer release later.	−USD 692,000 Exact value Exact value: -692000 USD 2019-01-01 – 2019-12-31: -692000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · DICERNA PHARMACEUTICALS INC · 2019-12-31 DICERNA PHARMACEUTICALS INC (edgar:1399529) Operating Cash Flow: -692000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T15:48:27Z Snapshot: 617957a68289bcdd08905de592adeaf6605088ace1dad10ef67585a7324ab889 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1399529/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -692000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000139952921000042/drna-20201231.htm#1497335 Filing: 000139952921000042 The citation records this snapshot. The page link may show a newer release later.	USD 6.35 million Exact value Exact value: 6349000 USD 2019-01-01 – 2019-12-31: 6349000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · DICERNA PHARMACEUTICALS INC · 2019-12-31 DICERNA PHARMACEUTICALS INC (edgar:1399529) Capital Expenditure: 6349000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T15:48:27Z Snapshot: 617957a68289bcdd08905de592adeaf6605088ace1dad10ef67585a7324ab889 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1399529/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 6349000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000139952921000042/drna-20201231.htm#1507948 Filing: 000139952921000042 The citation records this snapshot. The page link may show a newer release later.	−USD 7.04 million Calculation and evidence -692000 − 6349000 USD Exact free cash flow: -7041000 USD 2019-01-01 – 2019-12-31: -692000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 6349000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · DICERNA PHARMACEUTICALS INC · 2019-12-31 DICERNA PHARMACEUTICALS INC (edgar:1399529) Free cash flow: -7041000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T15:48:27Z Snapshot: 617957a68289bcdd08905de592adeaf6605088ace1dad10ef67585a7324ab889 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1399529?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -692000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000139952921000042/drna-20201231.htm#1497335 Filing: 000139952921000042 Input fundies:CapitalExpenditure: 6349000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000139952921000042/drna-20201231.htm#1507948 Filing: 000139952921000042 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 112.75 million Exact value Exact value: -112747000 USD 2020-01-01 – 2020-12-31: -112747000 USD Inspect Net Income Open source Share or cite Citation for Net Income · DICERNA PHARMACEUTICALS INC · 2020-12-31 DICERNA PHARMACEUTICALS INC (edgar:1399529) Net Income: -112747000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T15:48:27Z Snapshot: 617957a68289bcdd08905de592adeaf6605088ace1dad10ef67585a7324ab889 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1399529/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -112747000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000139952921000042/drna-20201231.htm#1443353 Filing: 000139952921000042 The citation records this snapshot. The page link may show a newer release later.	USD 175.11 million Exact value Exact value: 175112000 USD 2020-01-01 – 2020-12-31: 175112000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · DICERNA PHARMACEUTICALS INC · 2020-12-31 DICERNA PHARMACEUTICALS INC (edgar:1399529) Operating Cash Flow: 175112000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T15:48:27Z Snapshot: 617957a68289bcdd08905de592adeaf6605088ace1dad10ef67585a7324ab889 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1399529/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 175112000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000139952921000042/drna-20201231.htm#1496290 Filing: 000139952921000042 The citation records this snapshot. The page link may show a newer release later.	USD 11.75 million Exact value Exact value: 11747000 USD 2020-01-01 – 2020-12-31: 11747000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · DICERNA PHARMACEUTICALS INC · 2020-12-31 DICERNA PHARMACEUTICALS INC (edgar:1399529) Capital Expenditure: 11747000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T15:48:27Z Snapshot: 617957a68289bcdd08905de592adeaf6605088ace1dad10ef67585a7324ab889 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1399529/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 11747000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000139952921000042/drna-20201231.htm#1506962 Filing: 000139952921000042 The citation records this snapshot. The page link may show a newer release later.	USD 163.37 million Calculation and evidence 175112000 − 11747000 USD Exact free cash flow: 163365000 USD 2020-01-01 – 2020-12-31: 175112000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 11747000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · DICERNA PHARMACEUTICALS INC · 2020-12-31 DICERNA PHARMACEUTICALS INC (edgar:1399529) Free cash flow: 163365000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T15:48:27Z Snapshot: 617957a68289bcdd08905de592adeaf6605088ace1dad10ef67585a7324ab889 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1399529?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 175112000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000139952921000042/drna-20201231.htm#1496290 Filing: 000139952921000042 Input fundies:CapitalExpenditure: 11747000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1399529/000139952921000042/drna-20201231.htm#1506962 Filing: 000139952921000042 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

150 filings · 1,890 latest values · 1,898 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001399529, 1399529, DRNA, edgar:1399529

Also known as DICERNA PHARMACEUTICALS INC, DICERNA PHARMACEUTICALS, INC., Dicerna Pharmaceuticals Inc

DICERNA PHARMACEUTICALS INC

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2020 2020-01-01 – 2020-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation